Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FITZ vs PRME: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PRME Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

PRME Overall Winner 6-Pillar Tally: FITZ 1 – 4 PRME (1 Tie) Matrix Metrics: FITZ 2 – 6 PRME

As of Nov 16, 2026, Prime Medicine, Inc. (PRME) is the stronger overall head-to-head candidate over FITZ (FITZ) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FITZ carries a Unified Composite Score of 57.6/100 (HOLD) at $25.44 (N/M Forward P/E, N/A operating margin), whereas PRME carries 52.2/100 (HOLD) at $4.19 (N/M Forward P/E, -2584.2% operating margin).

  • Composite vs. Pillar Nuance: While FITZ currently prints a higher short-term Unified Composite Score (57.6/100 HOLD vs. PRME 52.2/100 HOLD), PRME captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-2584.2% vs. N/A operating margin) and revenue trajectory (+243.9% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FITZ vs PRME
FITZ US Equity
FITZ
Institutional Equity
$25.44
-2.15% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.00β · 27% Vol
Unified Composite Score
57.6 / 100 HOLD
Tech 45.0 Fund 59.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 43.0 · SMA20: $26.09 · SMA50: $25.92
PRME NASDAQ Head-to-Head Winner
Prime Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.19
-1.87% 1D
Market Cap $949.9M
TTM Revenue $7.1M
Forward P/E N/M
Beta / 30D Vol 2.45β · 149% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.8% over 20 days), RSI 52
RSI-14: 52.1 · SMA20: $4.32 · SMA50: $3.71

6-Pillar Scorecard Institutional Category Breakdown (FITZ 1 – 4 PRME)

Columns: Metric · FITZ · PRME
1. Valuation Multiples PRME
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 143.7x
2. Growth & Scale PRME
Revenue Growth (YoY) N/A +243.9%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $7.1M
Market Cap N/A $949.9M
3. Profitability & Quality PRME
Gross Margin N/A N/A
Operating Margin N/A -2584.2%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -207.2%
4. Balance Sheet & Cash Flow FITZ
Cash Generation (TTM) N/A -$157M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $65M Net Debt (0.06x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PRME
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile N/A (N/A) 218.0% (32nd %ile)
Put/Call OI Skew N/A 0.11x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FITZ (2) vs PRME (6)
Institutional Metric FITZ PRME Criterion Row Edge
Market Capitalization
Scale
N/A $949.9M Larger Scale PRME
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +243.9% Higher Growth PRME
Operating Margin (TTM)
Profitability
N/A -2584.2% Higher Margin PRME
Net Profit Margin
Profitability
N/A 0.0% Higher Margin PRME
Return on Equity (ROE)
Capital Efficiency
N/A -207.2% Higher ROE PRME
52-Week Range Position
Momentum
16% ($23–$36) 47% ($3–$6) Stronger Trend PRME
Beta / 30D Volatility
Risk Regime
1.00β · 27% Vol 2.45β · 149% Vol Lower Realized Risk FITZ
Unified Institutional Score
Composite Signal
57.6 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite FITZ
Trailing 12M Revenue (USD)
Operating Scale
N/A $7.1M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 143.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$157M ($65M Net Debt (0.06x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRME +22.49 pp
FITZ: -1.74% · PRME: +20.75%
3M Horizon PRME +38.28 pp
FITZ: -0.9% · PRME: +37.38%
6M Horizon PRME +22.73 pp
FITZ: +0.51% · PRME: +23.24%
1Y Horizon PRME +22.73 pp
FITZ: +0.51% · PRME: +23.24%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FITZ vs PRME. Trailing 12-month operating profitability (FITZ N/A vs PRME -2584.2%) and valuation multiples (FITZ N/M vs PRME N/M Forward P/E) are benchmarked directly in Pillar 4 below.

FITZ ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
PRME ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.1M
Gross MarginN/A
Op. Margin-2584.2%
ROE / Fwd P/E-207.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FITZ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FITZ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PRME SURGE
13d in phase · OBV ACCUMULATION
Current IV 218.0%
IV Percentile 32nd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PRME Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FITZ Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PRME Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $949.9M market capitalization and -2584.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FITZ vs PRME Key Questions & Quantitative Answers

As of Nov 16, 2026, Prime Medicine, Inc. (PRME) is the stronger overall head-to-head candidate over FITZ (FITZ) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FITZ carries a Unified Composite Score of 57.6/100 (HOLD) at $25.44 (N/M Forward P/E, N/A operating margin), whereas PRME carries 52.2/100 (HOLD) at $4.19 (N/M Forward P/E, -2584.2% operating margin). Composite vs. Pillar Nuance: While FITZ currently prints a higher short-term Unified Composite Score (57.6/100 HOLD vs. PRME 52.2/100 HOLD), PRME captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-2584.2% vs. N/A operating margin) and revenue trajectory (+243.9% vs. N/A YoY).

PRME leads the Growth & Scale pillar: FITZ posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with PRME at +243.9% YoY revenue growth and +0.0% YoY earnings growth on $7.1M TTM revenue (N/A gross margin, -2584.2% operating margin). On trailing 12-month operating scale, FITZ generates N/A in USD-normalized revenue versus $7.1M for PRME. In operating R&D and SG&A reinvestment, FITZ deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PRME.

PRME screens cheaper on headline valuation multiples. FITZ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PRME trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 143.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FITZ (N/A ROE) versus PRME (-207.2% ROE) capital efficiency.

In options market volatility and institutional positioning, FITZ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.00β · 27% Vol realized risk). By comparison, PRME carries 218.0% implied volatility (32nd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (2.45β · 149% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.